Egfr-mutant non-small-cell lung cancer at surgical stages: what is the place for tyrosine kinase inhibitors?

HIGHLIGHTS

• who: Xavier Cansouline and collaborators from the Department of Thoracic Surgery, Tours University Hospital, Chambray-Lès-Tours, France have published the research: EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?, in the Journal: Cancers 2022, 14, 2257. of 27/04/2022
• what: In this review, the authors aimed to assess the possible place for TKIs in standard care for EGFR-mutated NSCLC at the surgical stages in the upcoming years. The authors aimed to highlight the challenges regarding what could be the future of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.